Application of the biopharmaceutical classification system in clinical drug development - An industrial view

AAPS Journal

Volumn 10, Issue 2, 2008, Pages 306-310

  Cook, Jack ^a   Addicks, William ^b   Wu, Yunhui Henry ^c  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b Formulation Development Services   (India)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Biopharmaceutical classification system; Dissolution; Formulations development; Permeability; Solubility

Indexed keywords

GENERIC DRUG; PREGABALIN;

ADJUVANT THERAPY; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL RESEARCH; COST CONTROL; DIABETIC NEUROPATHY; DRUG APPROVAL; DRUG CLASSIFICATION; DRUG FORMULATION; DRUG MECHANISM; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG RELEASE; DRUG SOLUBILITY; FIBROMYALGIA; FOCAL EPILEPSY; GOVERNMENT REGULATION; HUMAN; MAXIMUM PLASMA CONCENTRATION; NEUROPATHIC PAIN; NONHUMAN; POSTHERPETIC NEURALGIA;

BIOPHARMACEUTICS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG INDUSTRY; DRUGS, GENERIC; PERMEABILITY; SOLUBILITY; THERAPEUTIC EQUIVALENCY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 53849122291     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-008-9036-5     Document Type: Article

References (14)

1. G. L. Amidon, H. Lennernäs, V. P. Shah, and J. R. Crison. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 12 (3):413-420 (1995).
2. E. Gupta, D. M. Barends, and E. Yamashita. Review of global regulations concerning biowaivers for immediate release solid oral dosage forms. Eur J Pharm Sci. 29: 315-324 (2006).
3. Lyrica® (pregabalin capsules) [product information]. Pfizer, Inc, New York, NY, 2007, Jun.
4. U.S. Food and Drug Administration, December 30, 2004. NDA 021446. Lyrica (pregabalin) Capsules Clinical Pharmacology Biopharmaceutics Review(s). CDER, FDA.
5. European Medicines Agency, 2004. H-C-546. Lyrica (pregabalin) European Public Assessment Report, Scientific Discussion. EMEA.
6. T. Takagi, C. Ramachandran, M. Bermejo, S. Yamashita, L. X. Yu, and G. L. Amidon. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan. Mol Pharm. 3: 631-643 (2006).
7. J. A. Cook, and H. N. Bockbrader. An industrial implementation of the biopharmaceutics classification system. Dissolution Technol. 9: 6-9 (2002).
8. D. M. Barends. BCS/BE in the Netherlands and Europe. Presented at the AAPS Workshop on BE, BCS, and Beyond, May 21- 23, 2007. North Bethesda, MD. Available at: http://www.aapspharmaceutica.com/meetings/files/90/ 35Barends.pdf. Accessed March 27, 2008.
9. Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. In: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) (2000).
10. Guidance for Industry: Immediate release Solid Dosage Forms. Scale-Up and Postapproval Changes. In: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) (1995).
11. T. Takagi, C. Ramachandran, M. Bermejo, S. Yamashita, L. X. Yu, and G. L. Amidon. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan. Mol Pharm. 3: 631-643 (2006).
12. M. Mehta. FDA Regulatory Use of BCS. Presented at the AAPS Workshop on BE, BCS, and Beyond, May 21-23, 2007. North Bethesda, MD. Available at: http://www.aapspharmaceutica.com/meetings/files/90/04Mehta.pdf. Accessed March 27, 2008.
13. J. E. Polli, L. X. Yu, and J. A. Cook. Summary workshop report: biopharmaceutics classification system - implementation challenges and extension opportunities. J Pharm Sci. 93: 1375-1381 (2004).
14. L. X. Yu, C. D. Ellison, D. P. Conner, L. J. Lesko, and A. S. Hussain. Influence of drug release properties of conventional solid dosage forms on the systemic exposure of highly soluble drugs. AAPS PharmSci. 3(3):E24 (2001)AvHilable at: http://www.aapspharmsci.org/view.asp?art= ps030324, Accessed March 27, 2008.